For the Inventor, By the Inventor

Enter assignee name

Basel, Switzerland

Basilea Pharmaceutica Ag

USPTO Granted Patents = 72

CIPO Patents = 8

EPO Patents = 28

Trademarks = 1

Forward Citations = 117

Loading Chart...

Loading Chart...

102 inventors (with patents filed for the assignee):

Felix Bachmann (16 out of 19 patents)

Heidi Alexandra Lane (9 out of 9 patents)

Johannes Laurenz Kellenberger (9 out of 10 patents)

4. Nobuo Shimma (7 out of 35 patents)

5. Jürg Dreier (7 out of 7 patents)

6. Lin Xu (7 out of 7 patents)

7. Franck Hubert Danel (6 out of 6 patents)

8. Martin Eberle (6 out of 21 patents)

9. Alessandro Strebel (6 out of 6 patents)

10. Subho Roy (6 out of 6 patents)

11. Goutam Saha (6 out of 6 patents)

12. Marc Muller (6 out of 16 patents)

13. Patrick Roussel (5 out of 14 patents)

14. Berangere Gaucher (5 out of 5 patents)

15. Eisaku Mizuguchi (5 out of 10 patents)

Core Competencies:

Phospho-Akt

Glu-Tubulin

Furazanobenzimidazoles

Isavuconazole

PDE4-Inhibiting Activity

Combination Therapy

Macrolides

Tricyclic Antibiotics

Bicyclic Antibiotics

Antifungal Composition

Substituted Benzimidazoles

Epoxy Triazole Derivatives

72 patents: Sort by Forward Citations

1. 10724072 - Use of phospho-Akt as a biomarker of drug response (2020-07-28),

2. 10656162 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles (2020-05-19),

3. 10590092 - Process for the manufacture of isavuconazole or ravuconazole (2020-03-17),

4. 10222377 - Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles (2019-03-05),

5. 10221206 - Selected macrolides with PDE4-inhibiting activity (2019-03-05),

6. 10067120 - Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles (2018-09-04),

7. 10006078 - Use of phospho-Akt as a biomarker of drug response (2018-06-26),

8. 9995754 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles (2018-06-12),

9. 9970938 - Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles (2018-05-15),

10. 9783508 - Process for the manufacture of isavuconazole or ravuconazole (2017-10-10),

11. 9738676 - Selected macrolides with PDE4-inhibiting activity (2017-08-22),

12. 9511064 - Combination therapy for the treatment of cancer and immunosuppression (2016-12-06),

13. 9476889 - Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles (2016-10-25),

14. 9366682 - Use of stathmin as a biomarker of drug response to furazanobenzimidazoles (2016-06-14),

15. 9346799 - Useful combinations of monobactam antibiotics with beta-lactamase inhibitors (2016-05-24),

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines to meet the medical needs of patients with serious and life-threatening conditions. With a particular emphasis on infectious diseases and oncology, Basilea is dedicated to improving patients’ lives through its research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

72 Patents

#9 in Basel

#208 in Switzerland

#10,081 in the World

Basel, Switzerland

Basilea Pharmaceutica Ag

Forward Citations = 117

102 inventors:

Felix Bachmann (16 out of 19 patents)

Heidi Alexandra Lane (9 out of 9 patents)

Johannes Laurenz Kellenberger (9 out of 10 patents)

4. Nobuo Shimma (7 out of 35 patents)

5. Jürg Dreier (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…